| Sep 4, 2026Latest represented filing date | Krystal Biotech, Inc. (KRYS)Nasdaq | Current covered snapshotPresident, R&D · Director · 10% ownerValuation observation Sep 25, 2026 | Common Stock: 1,302,145 sharesCurrent covered company value: $450.48M | Published current ownership snapshotForms represented: 4Owner filingsIssuer filings |
| Sep 4, 2026Filed date | Krystal Biotech, Inc. (KRYS)Nasdaq | SaleSEC code SEffective Sep 4, 2026 · transaction dateReported units 2,006 shares · reported price 355.5719 | Common StockReported position after transaction: 1,324,619 shares | 4 filing0001298711-26-000009 |
| Sep 4, 2026Filed date | Krystal Biotech, Inc. (KRYS)Nasdaq | SaleSEC code SEffective Sep 4, 2026 · transaction dateReported units 1,329 shares · reported price 364.4771 | Common StockReported position after transaction: 1,303,370 shares | 4 filing0001298711-26-000009 |
| Sep 4, 2026Filed date | Krystal Biotech, Inc. (KRYS)Nasdaq | SaleSEC code SEffective Sep 4, 2026 · transaction dateReported units 826 shares · reported price 365.4139 | Common StockReported position after transaction: 1,302,544 shares | 4 filing0001298711-26-000009 |
| Sep 4, 2026Filed date | Krystal Biotech, Inc. (KRYS)Nasdaq | SaleSEC code SEffective Sep 4, 2026 · transaction dateReported units 399 shares · reported price 366.556 | Common StockReported position after transaction: 1,302,145 shares | 4 filing0001298711-26-000009 |
| Sep 4, 2026Filed date | Krystal Biotech, Inc. (KRYS)Nasdaq | SaleSEC code SEffective Sep 4, 2026 · transaction dateReported units 3,267 shares · reported price 356.3679 | Common StockReported position after transaction: 1,321,352 shares | 4 filing0001298711-26-000009 |
| Sep 4, 2026Filed date | Krystal Biotech, Inc. (KRYS)Nasdaq | SaleSEC code SEffective Sep 4, 2026 · transaction dateReported units 3,962 shares · reported price 357.5742 | Common StockReported position after transaction: 1,317,390 shares | 4 filing0001298711-26-000009 |
| Sep 4, 2026Filed date | Krystal Biotech, Inc. (KRYS)Nasdaq | SaleSEC code SEffective Sep 4, 2026 · transaction dateReported units 3,180 shares · reported price 358.4203 | Common StockReported position after transaction: 1,314,210 shares | 4 filing0001298711-26-000009 |
| Sep 4, 2026Filed date | Krystal Biotech, Inc. (KRYS)Nasdaq | SaleSEC code SEffective Sep 4, 2026 · transaction dateReported units 3,392 shares · reported price 359.3862 | Common StockReported position after transaction: 1,310,818 shares | 4 filing0001298711-26-000009 |
| Sep 4, 2026Filed date | Krystal Biotech, Inc. (KRYS)Nasdaq | SaleSEC code SEffective Sep 4, 2026 · transaction dateReported units 2,320 shares · reported price 360.466 | Common StockReported position after transaction: 1,308,498 shares | 4 filing0001298711-26-000009 |
| Sep 4, 2026Filed date | Krystal Biotech, Inc. (KRYS)Nasdaq | SaleSEC code SEffective Sep 4, 2026 · transaction dateReported units 1,242 shares · reported price 361.61 | Common StockReported position after transaction: 1,307,256 shares | 4 filing0001298711-26-000009 |
| Sep 4, 2026Filed date | Krystal Biotech, Inc. (KRYS)Nasdaq | SaleSEC code SEffective Sep 4, 2026 · transaction dateReported units 1,992 shares · reported price 362.6527 | Common StockReported position after transaction: 1,305,264 shares | 4 filing0001298711-26-000009 |
| Sep 4, 2026Filed date | Krystal Biotech, Inc. (KRYS)Nasdaq | SaleSEC code SEffective Sep 4, 2026 · transaction dateReported units 565 shares · reported price 363.3404 | Common StockReported position after transaction: 1,304,699 shares | 4 filing0001298711-26-000009 |